HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS

描述：（改编自申请人的摘要）主要目标 该计划的一个重要部分是开发异源结合肽疫苗 针对单纯疱疹病毒，以预防或治疗人类感染。 的 异源缀合肽疫苗将由表位构建 T细胞识别的单纯疱疹病毒蛋白， 预测与T细胞结合的肽（T细胞结合配体 （TCBL））。 TCBL似乎增强了免疫原性。 抗原肽，并指导免疫应答的过程， 更多的细胞（TH 1）或体液（TH 2）。 这些杂合物 将测试它们引发保护性免疫反应的能力 HSV-1和HSV-2在HSV疾病的小鼠模型中的作用。 TCBL是 来自不同淋巴细胞表面结合蛋白的肽序列。 成功的疫苗将引发TH 1型（包括延迟型 超敏性）保护性免疫应答 小鼠模型。 HSV疫苗将成为开发的原型 用于治疗或预防由其他 传染源 拟定商业应用： 超过60，000，000例HSV感染表明迫切需要HSV疫苗。 在美国被感染并患有复发性HSV的人 潜伏病毒感染。第一个目标，治疗性疫苗 可以极大地减少和/或消除 复发感染的严重程度和数量。第二个目标是a HSV的预防性疫苗，以消除潜在的原因， 最终对消除潜伏感染产生重大影响，如果 疫苗诱导了绝育免疫。第二个目标也是 不需要达到治疗性疫苗的第一目的。 Cel-Sci正在开发一种类似的艾滋病毒疫苗方法， 在欧洲进行预防性疫苗的II期试验，以评估其 免疫原性该公司预计将在非洲开始第二阶段的试验， 在6个月内Cel-Sci计划启动一项针对艾滋病毒的I期试验， 在美国使用这种L.E.A.P.S. 一年内的技术。

DESCRIPTION: (Adapted from the applicant's abstract) The primary goal of this program is the development of heteroconjugate peptide vaccines against herpes simplex virus to prevent or treat human infections. The heteroconjugate peptide vaccines will be constructed of epitopes from herpes simplex virus proteins which are recognized by T cells and peptides which are predicted to bind to T cells (T cell binding ligands (TCBL)). The TCBL appears to potentiate the immunogenicity of the antigenic peptide and to guide the course of the immune response to be either more cellular (TH1) or humoral (TH2). These heteroconjugates will be tested for their ability to elicit protective immune responses to HSV-1 and HSV-2 in mouse models for HSV disease. The TCBL are peptide sequences from different lymphocyte surface binding proteins. The successful vaccine will elicit TH1 type (including delayed type hypersensitivity) protective immune responses to viral challenge in mouse models. The HSV vaccines will be prototypes for the development of heteroconjugate vaccines to treat or prevent disease by other infectious agents. PROPOSED COMMERCIAL APPLICATION: The urgent need for a vaccine for HSV is shown by the over 60,000,000 persons in the U.S. being infected and subject to recurrent HSV infections from laten virus. The first objective, a therapeutic vaccine could be of tremendous benefit in reducing and/or eliminating the severity and number of recurrent infections. The second objective, a preventive vaccine of HSV to eliminate the underlying cause could ultimately have a major impact in eliminating latent infections, if the vaccine induced a sterilizing immunity. The second objective also does not require the first objective of a therapeutic vaccine be reached. Cel-Sci is developing a similar approach for a HIV vaccine and is in phase II trials in Europe for a preventive vaccine to evaluate its immunogenicity. the Company expects to start a phase II trial in Africa within 6 months. Cel-Sci has plans to start a phase I trial for a HIV therapeutic vaccine candidate in the U.S. using this L.E.A.P.S. technology within a year.